# A Trial of SP2086 With Hepatic Insufficiency

> **NCT06035406** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Retagliptin Phosphate Tablet

## Key facts

- **NCT ID:** NCT06035406
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035406, "A Trial of SP2086 With Hepatic Insufficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06035406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*